Artal Group’s Fate Therapeutics FATE Stock Holding History

Artal Group’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200,000	Closed	-$3.91M	–	105
2019 Q4	$3.91M	Buy	+200,000	New	+$3.18M	0.15%	79

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Artal Group's FATE Position: Q3 2024 in Review

Artal Group sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 1,032,500 shares — an estimated $3.39M sold.

Artal Group first reported a position in FATE in Q1 2018 and held it in 23 quarters. The position peaked at $127M in Q4 2020. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

Artal Group reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 1,032,500 Fate Therapeutics shares in Q3 2024, an estimated $3.39M.
Artal Group first reported a position in Fate Therapeutics in Q1 2018 and held it in 23 quarters.
Artal Group's Fate Therapeutics position peaked at $127M in Q4 2020.
164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.